NIOX Group (LON:NIOX) Given New GBX 86 Price Target at Deutsche Bank Aktiengesellschaft

Posted by Patrick Bannon on Jan 21st, 2026

NIOX Group (LON:NIOX – Get Free Report) had its price objective reduced by research analysts at Deutsche Bank Aktiengesellschaft from GBX 90 to GBX 86 in a research note issued on Wednesday,Digital Look reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential upside of 30.30% from the company’s current price.

NIOX Group Price Performance

LON NIOX traded up GBX 0.20 on Wednesday, hitting GBX 66. 3,223,913 shares of the company’s stock were exchanged, compared to its average volume of 1,229,676. The stock has a 50-day moving average of GBX 68.97 and a 200-day moving average of GBX 70.25. The company has a current ratio of 6.31, a quick ratio of 1.94 and a debt-to-equity ratio of 1.10. NIOX Group has a 52 week low of GBX 53.40 and a 52 week high of GBX 77.60. The stock has a market cap of £275.81 million, a price-to-earnings ratio of 52.80 and a beta of 0.92.

Insiders Place Their Bets

In related news, insider Sarah Duncan acquired 5,522 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was acquired at an average cost of GBX 71 per share, for a total transaction of £3,920.62. 4.88% of the stock is owned by company insiders.

NIOX Group Company Profile

(Get Free Report)

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.